Search

Displaying results 6501 - 6510 of 10000 in total
  1. Drug

    Rivoglitazone

    go.drugbank.com/drugs/DB09200
    Investigational

    Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.

  2. Drug

    Fosinoprilat

    go.drugbank.com/drugs/DB14207
    Experimental

    Fosinoprilat is the active phosphinic acid metabolite of prodrug [fosinopril], which is activated by esterases in vivo. It binds zinc with phosphinic acid group.

  3. Drug

    IP-2018

    go.drugbank.com/drugs/DB19049
    Investigational

    IP-2018 is under investigation in clinical trial NCT04686916 (Clinical Trial Studying the Efficacy and Safety of IP2018 in Depressed, Erectile Dysfunction (ED) Patients).

  4. Drug

    Olvimulogene nanivacirepvec

    go.drugbank.com/drugs/DB16268
    Investigational

    Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).

    Synonyms: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
  5. Drug

    AUM-601

    go.drugbank.com/drugs/DB17382
    Experimental

    AUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.

    Synonyms: HL 5101
  6. Drug

    Tonabersat

    go.drugbank.com/drugs/DB06578
    Investigational

  7. Drug

    FG-2216

    go.drugbank.com/drugs/DB08687
    Investigational

    A orally active prolyl-hydroxylase inhibitor which can stabilize hypoxia-inducible transcription factor independent of oxygen availability.

    Synonyms: (((1-Chloro-4-hydroxyisoquinolin-3-yl)carbonyl)amino)acetic acid
  8. Drug

    Favezelimab

    go.drugbank.com/drugs/DB16729
    Investigational

    Favezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A

  9. Drug

    Oremepermin alfa

    go.drugbank.com/drugs/DB27148
    Investigational

    Oremepermin alfa is a recombinant human hepatocyte growth factor (isoform 3) and glycoprotein composed of an α-chain and a β-chain.[L54006] It is produced in CHO cells.[L54006]

  10. Drug

    Sirpiglenastat

    go.drugbank.com/drugs/DB17536
    Investigational

    It is under investigation in clinical trial NCT04471415 (Study to Investigate DRP-104 in Adults With Advanced Solid Tumors). … Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a broad-acting glutamine antagonist.

    Synonyms: L-norleucine, n-acetyl-l-tryptophyl-6-diazo-5-oxo-, 1-methylethyl ester, Propan-2-yl (2s)-2-((n-acetyl-l-tryptophyl)amino)-6-diazo-5-oxohexanoate